
Viking Therapeutics jumps 26.5% on strong GLP-1 obesity drug data, while peers show little reaction.
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...





